Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Longeveron Inc. (LGVN)

Longeveron CMO Nataliya Agafonova to step down effective October 14, 2026

Neutral Impact 3 of 5 leadership Written later

Longeveron Inc. disclosed that Chief Medical Officer Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down, effective October 14, 2026. The filing does not state a successor or the reason for her departure.

Key points

  • Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down as Chief Medical Officer.
  • The departure takes effect October 14, 2026.
  • The filing does not name a replacement or give a reason for the departure.

The filing

CompanyLongeveron Inc. (LGVN)
Form8-K, current report
Filed with the SECOct 14, 2026, 4:01 PM ET
Accession number0001213900-26-109411

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.